Literature DB >> 16688803

Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.

Stanislas Bruley des Varannes1, Sylvie Sacher-Huvelin, Fabienne Vavasseur, Claude Masliah, Marc Le Rhun, Philippe Aygalenq, Sylvie Bonnot-Marlier, Yves Lequeux, Jean Paul Galmiche.   

Abstract

AIM: To determine the diagnostic value of the rabeprazole test in patients seen by general practitioners.
METHODS: Eighty-three patients with symptoms suggestive of GERD were enrolled by general practitioners in this multi-centre, randomized and double-blind study. All patients received either rabeprazole (20 mg bid) or a placebo for one week. The diagnosis of GERD was established on the presence of mucosal breaks at endoscopy and/or an abnormal esophageal 24-h pH test. The test was considered to be positive if patients reported at least a "clear improvement" of symptoms on a 7-point Likert scale.
RESULTS: The sensitivities of the test for rabeprazole and the placebo were 83% and 40%, respectively. The corresponding specificity, positive and negative predictive values were 45% and 67%, 71% and 71%, and 62% and 35%, respectively. A receiver operating characteristics (ROC) analysis confirmed that the best discriminatory cut-off corresponded to description of "clear improvement".
CONCLUSION: The poor specificity of the proton-pump inhibitor (PPI) test does not support such an approach to establish a diagnosis of GERD in a primary care setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16688803      PMCID: PMC4087990          DOI: 10.3748/wjg.v12.i16.2569

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

1.  Rabeprazole: pharmacology, pharmacokinetics, and potential for drug interactions. Introduction.

Authors:  G Sachs; T J Humphries
Journal:  Aliment Pharmacol Ther       Date:  1999-08       Impact factor: 8.171

2.  Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.

Authors:  Kayoko Oda; Ryuichi Iwakiri; Megumi Hara; Kazuyo Watanabe; Akiko Danjo; Ryo Shimoda; Atsushi Kikkawa; Akifumi Ootani; Hiroyuki Sakata; Seiji Tsunada; Kazuma Fujimoto
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 3.  Empirical trials in treatment of gastroesophageal reflux disease.

Authors:  R Fass
Journal:  Dig Dis       Date:  2000       Impact factor: 2.404

4.  One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease.

Authors:  F Johnsson; J G Hatlebakk; A C Klintenberg; J Román; E Toth; A Stubberöd; A Falk; R Edin
Journal:  Scand J Gastroenterol       Date:  2003-04       Impact factor: 2.423

5.  Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.

Authors:  T Saitoh; Y Fukushima; H Otsuka; J Hirakawa; H Mori; T Asano; T Ishikawa; T Katsube; K Ogawa; S Ohkawa
Journal:  Aliment Pharmacol Ther       Date:  2002-10       Impact factor: 8.171

6.  Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.

Authors:  Philip Miner; William Orr; Joseph Filippone; Leonard Jokubaitis; Sheldon Sloan
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

7.  Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics.

Authors:  Mattijs E Numans; Joseph Lau; Niek J de Wit; Peter A Bonis
Journal:  Ann Intern Med       Date:  2004-04-06       Impact factor: 25.391

8.  Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.

Authors:  D Pantoflickova; G Dorta; M Ravic; P Jornod; A L Blum
Journal:  Aliment Pharmacol Ther       Date:  2003-06-15       Impact factor: 8.171

9.  pH probe positioning for 24-hour pH-metry by manometry or pH step-up.

Authors:  Christian Pehl; Ilona Boccali; Michael Hennig; Wolfgang Schepp
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-04       Impact factor: 2.566

10.  Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.

Authors:  S Warrington; K Baisley; M Boyce; B Tejura; A Morocutti; N Miller
Journal:  Aliment Pharmacol Ther       Date:  2002-07       Impact factor: 8.171

View more
  2 in total

1.  A multicenter, randomized, comparative study to determine the appropriate dose of lansoprazole for use in the diagnostic test for gastroesophageal reflux disease.

Authors:  Si Hyung Lee; Byung Ik Jang; Seong Woo Jeon; Joong Goo Kwon; Eun Young Kim; Kwang-Bum Cho; Chang Geun Park; Chang Heon Yang
Journal:  Gut Liver       Date:  2011-08-18       Impact factor: 4.519

2.  Assessing different diagnostic tests for gastroesophageal reflux disease: a systematic review and network meta-analysis.

Authors:  Mengyu Zhang; John E Pandolfino; Xuyu Zhou; Niandi Tan; Yuwen Li; Minhu Chen; Yinglian Xiao
Journal:  Therap Adv Gastroenterol       Date:  2019-11-21       Impact factor: 4.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.